Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer

Inclusion Criteria: * Histologically confirmed adenocarcinoma of the pancreas * Prior failed 1st line gemcitabine therapy for metastatic disease or relapsed within six months of completion of gemcitabine adjuvant therapy * Prior capecitabine or 5fu is allowed in the setting of radiation * Must either be able to swallow or receive enteral nutrition via gastrostomy feeding tube * Cardiac ejection fraction within institutional range of normal as measured by echocardiogram * ECOG performance status 0-2 * Signed informed consent form * Adequate hepatic, bone marrow, and renal function Exclusion Criteria: * Any prior treatment with lapatinib, or any anti-HER2 treatment or any anti-EGFR treatment * Not recovered from adverse events to a toxicity grade \</= 1 due to prior chemotherapy * More than one prior chemotherapy regimens * Known brain metastases, uncontrolled seizure disorders, encephalitis, or multiple sclerosis * HIV positive on antiretroviral therapy * Pregnant or lactating * History of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib or capecitabine * Malabsorption syndrome or uncontrolled inflammatory GI disease (Crohn's or ulcerative colitis) * Known history of uncontrolled or symptomatic angina, arrhythmia, or congestive heart failure * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/ social situations that would limit compliance with study requirements * Known dihydropyrimidine dehydrogenase deficiency * Concurrent malignancy unless the subject has been curatively treated and disease free for \>/= 2 years or the cancer was non-melanoma skin cancer or early cervical cancer. * Creatinine clearance \< 30 mL/min * Absolute neutrophil count \< 1500, platelets \< 75,000 * Transaminases \> 3.0 times the upper limit of normal, except in known hepatic metastasis, wherein they must be \< 5.0 times the upper limit of normal * Total bilirubin \> 1.5 times the ULN, \> 2.5 x ULN if patient has Gilbert's syndrome